B-Cell Non-Hodgkin Lymphoma: Extended Follow-up With Mosunetuzumab
Extended follow-up of the dose-escalation phase of a phase I/II trial showed that the CD20 x CD3 T-cell–engaging bispecific antibody mosunetuzumab-axgb—given as an off-the-shelf fixed-duration outpati…